← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
FROST PHILLIP MD ET AL
10% Owner | Chief Executive Officer | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0000898860
Purchase history
- Companies traded
- 3
- Purchases · 12M
- 14
- Purchases · 24M
- 32
- Average purchase
- $291.2K
- Median purchase
- $192.5K
- Gross purchase value
- $9.3M
Companies: Cocrystal Pharma, Inc. | NOCOPI TECHNOLOGIES INC/MD/ | OPKO HEALTH, INC.
32 SEC accession(s) · 23 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-08-06 | Cocrystal Pharma, Inc. | COCP | Director | 10% Owner | $9.8K | Open filing |
| 2026-08-05 | Cocrystal Pharma, Inc. | COCP | Director | 10% Owner | $70.5K | Open filing |
| 2026-02-25 | Cocrystal Pharma, Inc. | COCP | Director | 10% Owner | $20.0K | Open filing |
| 2026-02-09 | Cocrystal Pharma, Inc. | COCP | Director | 10% Owner | $47.5K | Open filing |
| 2026-01-02 | Cocrystal Pharma, Inc. | COCP | Director | 10% Owner | $47.5K | Open filing |
| 2025-12-31 | Cocrystal Pharma, Inc. | COCP | Director | 10% Owner | $19.4K | Open filing |
| 2025-12-29 | Cocrystal Pharma, Inc. | COCP | Director | 10% Owner | $63.0K | Open filing |
| 2025-11-28 | Cocrystal Pharma, Inc. | COCP | Director | 10% Owner | $4.0K | Open filing |
| 2025-11-25 | Cocrystal Pharma, Inc. | COCP | Director | 10% Owner | $18.8K | Open filing |
| 2025-11-21 | OPKO HEALTH, INC. | OPK | Chief Executive Officer | $770.2K | Open filing |
| 2025-11-20 | OPKO HEALTH, INC. | OPK | Chief Executive Officer | $772.4K | Open filing |
| 2025-11-19 | OPKO HEALTH, INC. | OPK | Chief Executive Officer | $760.6K | Open filing |
| 2025-11-18 | OPKO HEALTH, INC. | OPK | Chief Executive Officer | $680.8K | Open filing |
| 2025-10-31 | OPKO HEALTH, INC. | OPK | Chief Executive Officer | $213.0K | Open filing |
| 2025-08-08 | OPKO HEALTH, INC. | OPK | Chief Executive Officer | $891.0K | Open filing |
| 2025-06-10 | NOCOPI TECHNOLOGIES INC/MD/ | NNUP | 10% Owner | $215.4K | Open filing |
| 2025-04-10 | OPKO HEALTH, INC. | OPK | Chief Executive Officer | $170.0K | Open filing |
| 2025-04-08 | OPKO HEALTH, INC. | OPK | Chief Executive Officer | $185.0K | Open filing |
| 2025-04-01 | OPKO HEALTH, INC. | OPK | Chief Executive Officer | $165.0K | Open filing |
| 2025-03-28 | OPKO HEALTH, INC. | OPK | Chief Executive Officer | $255.0K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 1/30
- Large purchase ≥ $100k
- 22/32
- Cluster buying · 15D
- 23/32
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.